Evidence map›Paper›PMID 34718324›Full record

Trial reportBlood cancer journal2021

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia.

Joshua F Zeidner, Tara L Lin, Carlos E Vigil, Gil Fine, M Yair Levy, Aziz Nazha, Jordi Esteve, Daniel J Lee, Karen Yee, Andrew Dalovisio and 15 more

Open access · goldAbstract readClinical Trial, Phase IILetterMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Haematologica · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 20 institutions in 4 countries.

Joshua F ZeidnerUniversity of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA. Joshua_Zeidner@med.unc.edu.ORCID 0000-0002-9014-1514
Tara L LinUniversity of Kansas Medical Center, Kansas City, KS, USA.
Carlos E VigilUniversity of Iowa, Iowa City, IA, USA.
Gil FineSumitomo Dainippon Pharma Oncology, Lehi, UT, USA.
M Yair LevyTexas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA.
Aziz NazhaCleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
Jordi EsteveHospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0002-8056-648X
Daniel J LeeColumbia University Irving Medical Center, New York, NY, USA.
Karen YeePrincess Margaret Cancer Centre, Toronto, ON, Canada.
Andrew DalovisioOchsner Medical Center, New Orleans, LA, USA.
Eunice S WangRoswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Juan M Bergua BurguesHospital San Pedro de Alacantra, Caceres, Spain.
Jeffrey SchriberCancer Treatment Centers of America, Phoenix, AZ, USA.
Mark R LitzowMayo Clinic, Rochester, MN, USA.ORCID 0000-0002-9816-6302
Olga FrankfurtRobert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Teresa Bernal Del CastilloHospital Universitario Central de Asturias, Asturias, Spain.
Vijaya Raj BhattFred and Pamela Buffet Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.ORCID 0000-0003-2513-0533
Bhavana BhatnagarThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Priyanka MehtaUniversity Hospitals Bristol, Bristol, UK.
Richard DillonDepartment of Medical and Molecular Genetics, King's College, London, UK.
Maria Vidriales VicenteHospital Clinico Universitario de Salamanca, Salamanca, Spain.ORCID 0000-0001-5049-3673
Stephen AnthonySumitomo Dainippon Pharma Oncology, Lehi, UT, USA.
David BearssSumitomo Dainippon Pharma Oncology, Lehi, UT, USA.
Pau Montesinos *Hospital Universitario Politecnico La Fe, Valencia, Spain.ORCID 0000-0002-3275-5593
B Douglas Smith *Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Northwestern University · USSumitomo Dainippon Pharma (United States) · USCancer Treatment Centers of America · USCleveland Clinic · USColumbia University Irving Medical Center · USComplejo Hospitalario de Salamanca · ESHospital Clínic de Barcelona · ESHospital San Pedro de Alcántara · ESHospital Universitari i Politècnic La Fe · ESHospital Universitario Central de Asturias · ESJohns Hopkins University · USKing's College London · GBMayo Clinic in Arizona · USOchsner Medical Center · USPrincess Margaret Cancer Centre · CARoswell Park Comprehensive Cancer Center · USTexas Oncology · USThe Ohio State University · USUniversity Hospitals Bristol NHS Foundation Trust · GBUniversity of Kansas Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsMyeloid Cell Leukemia Sequence 1 ProteinAdolescentAdultAgedBiomarkers, TumorCytarabineFemaleFlavonoidsHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMitoxantronePiperidinesalvocidibBiomarkers, TumorCytarabineFlavonoidsMCL1 protein, humanMitoxantroneMyeloid Cell Leukemia Sequence 1 ProteinPiperidines

Identifiers

PMID34718324
PMCPMC8557202
OpenAlexW3208762835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.